



Astec LifeSciences Ltd.

Date: 27th July, 2023

To,
BSE Limited
P. J. Towers, Dalal Street, Fort
Mumbai – 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai-400 051

Ref.: BSE Scrip Code No. "533138"

Ref.: "ASTEC"

Sub.: Outcome of the Board Meeting

Pursuant to Regulations 30, 33 and 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Schedule III to the said Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e., on Thursday, 27th July, 2023 (which commenced at 2.00 p.m. and concluded at 03.02 p.m.), *inter alia*, has approved / noted the following:

- (a) Upon recommendation of the Audit Committee, the Board of Directors has approved the Unaudited Financial Results (Standalone & Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter ended 30th June, 2023 (enclosed herewith).
- (b) The Board of Directors took note of the Limited Review Report of the Statutory Auditors on the Unaudited Financial Results (Standalone & Consolidated) for the Quarter ended 30th June, 2023 (enclosed herewith).

The Limited Review Report of the Statutory Auditors is with unmodified opinion with respect to the Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter ended 30th June, 2023.

Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)
Encl.: As above



Regd. Office :
"Godrej One", 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai-400079,
Maharashtra, India
Telephone No.: 022- 25188010
Fax No.: 022-22618289
Email id: astecinfo@godrejastec.com
Website: www.astecsl.com
CIN : L99999MH1994PLC076236

**Astec Life Sciences Limited**

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsls.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

Statement of Unaudited Standalone Financial Results for the Quarter ended 30th June, 2023



Rs. in Lakh

Sr. No	Particulars	STANDALONE			
		Quarter ended		Year ended	
		30-Jun-23 (Unaudited)	31-Mar-23 (Audited)	30-Jun-22 (Unaudited)	31-Mar-23 (Audited)
I	Revenue from Operations	14,284.86	12,697.20	18,426.63	62,816.62
II	Other Income	169.71	256.62	270.67	1,303.62
III	Total Income (I+II)	14,454.57	12,953.82	18,697.30	64,120.24
IV	Expenses				
	Cost of materials consumed	12,076.64	7,649.10	13,863.65	46,083.46
	Changes in inventories of finished goods and work-in-progress	(1,815.71)	975.51	(1,615.51)	(5,959.03)
	Employee benefits expense	1,538.03	1,285.68	1,297.78	5,225.88
	Finance costs	646.68	640.50	393.03	2,074.01
	Depreciation and amortisation expense	940.04	777.47	894.23	3,371.19
	Other expenses.	2,172.38	2,246.61	2,335.43	9,839.82
	Total expenses (IV)	15,558.06	13,574.87	17,168.61	60,635.33
V	Profit / (loss) before exceptional items and tax (III - IV)	(1,103.49)	(621.05)	1,528.69	3,484.91
VI	Exceptional Items	-	-	-	-
VII	Profit / (loss) before tax (V-VI)	(1,103.49)	(621.05)	1,528.69	3,484.91
VIII	Tax Expense:				
	(1) Current tax	-	(102.39)	98.63	-
	(2) Deferred tax	(282.79)	(19.13)	291.08	932.87
IX	Profit / (loss) for the period/year from continuing operations (VII-VIII)	(820.70)	(499.53)	1,138.98	2,552.04
X	Profit / (loss) from discontinuing operations	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-
XII	Profit / (loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-
XIII	Profit / (loss) for the period/year (IX + XII)	(820.70)	(499.53)	1,138.98	2,552.04
XIV	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	(0.50)	(29.08)	(0.50)	(30.58)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.13	7.32	0.13	7.70
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV	Total Comprehensive Income for the period/year (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period/year)	(821.07)	(521.29)	1,138.61	2,529.16
XVI	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,960.61	1,960.57	1,959.76	1,960.57
XVII	Other Equity excluding Revaluation Reserve	-	-	-	39,918.80
XVIII	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinuing operations) (non-annualised) :				
	(1) Basic (in Rs.)	(4.19)	(2.55)	5.81	13.02
	(2) Diluted (in Rs.)	(4.19)	(2.55)	5.81	13.02

Notes:

- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Thursday, 27th July, 2023.
- The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to limited review by the Statutory Auditors of the Company and they have expressed an unmodified review report.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The figures for the Quarter ended 31st March, 2023 are the balancing figures between audited figures in respect of the full financial year 2022-23 and the published year to date figures upto the third quarter of the financial year 2022-23. Also the figures upto the end of the third quarter had only been reviewed and not subjected to audit.
- The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards employment and post-employment benefits. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its valuation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- In April 2023, Astec LifeSciences launched a new state-of-the-art research and development (R&D) Center in Maharashtra, named the 'Adi Godrej Center for Chemical Research and Development'. R&D Center is equipped with a synthesis lab for product synthesis, a formulation lab to develop new formulations and also houses sophisticated process safety infrastructure to undertake safe and sustainable chemical reactions. The new facility will focus on new product generation, process optimization & scale-up along with product life-cycle management and help Astec in providing services to innovator companies in the contract development & manufacturing space (CDMO).

For Astec LifeSciences Limited

ANURAG ROY
Digitally signed by
ANURAG ROY
Date: 2023.07.27
14:25:00 +05'30'

Anurag Roy

Whole – Time Director & Chief Executive Officer

DIN : 07444595

Place : Mumbai

Date : 27th July, 2023

BURJIS TEHMURASP PARDIWALA
Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2023.07.27
14:38:43 +05'30'

Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

Statement of Unaudited Consolidated Financial Results for the Quarter ended 30th June, 2023



ASTEC



Rs. in Lakh

Sr. No	Particulars	CONSOLIDATED			
		Quarter Ended			Year ended
		30-Jun-23	31-Mar-23	30-Jun-22	31-Mar-23
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from Operations	14,284.86	12,697.20	18,426.63	62,816.62
II	Other Income	170.86	257.49	271.04	1,306.01
III	Total Income (I+II)	14,455.72	12,954.69	18,697.67	64,122.63
IV	Expenses				
	Cost of materials consumed	12,076.64	7,649.07	13,863.65	46,083.44
	Changes in inventories of finished goods and work-in-progress	(1,815.71)	975.51	(1,615.51)	(5,959.03)
	Employee benefits expense	1,538.03	1,285.68	1,297.78	5,225.88
	Finance costs	646.22	639.85	392.39	2,071.43
	Depreciation and amortisation expense	938.56	776.00	892.74	3,365.25
	Other expenses.	2,172.66	2,246.91	2,335.69	9,840.93
	Total expenses (IV)	15,556.40	13,573.02	17,166.74	60,627.89
V	Profit / (loss) before exceptional items and tax (III - IV)	(1,100.68)	(618.34)	1,530.93	3,494.73
VI	Exceptional Items	-	-	-	-
VII	Profit / (loss) before tax (V-VI)	(1,100.68)	(618.34)	1,530.93	3,494.73
VIII	Tax Expense:				
	(1) Current tax	0.81	(101.65)	99.24	2.67
	(2) Deferred tax	(282.89)	(19.18)	291.03	932.67
IX	Profit / (loss) for the period/year from continuing operations (VII-VIII)	(818.60)	(497.51)	1,140.66	2,559.40
X	Profit / (loss) from discontinuing operations	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-
XII	Profit / (loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-
XIII	Profit / (loss) for the period/year (IX + XII)	(818.60)	(497.51)	1,140.66	2,559.40
XIV	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	(0.50)	(29.08)	(0.50)	(30.58)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.13	7.32	0.13	7.70
	B (i) Items that will be reclassified to profit or loss	-	(0.09)	0.46	1.06
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV	Total Comprehensive Income for the period/year (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period/year)	(818.97)	(519.36)	1,140.75	2,537.58
XVI	Net Profit/(loss) attributable to:				
	- Owners	(819.46)	(498.33)	1,139.99	2,556.49
	- Non controlling interests	0.86	0.81	0.67	2.90
	Total Comprehensive Income attributable to:				
	- Owners	(819.83)	(520.15)	1,140.08	2,534.67
	- Non controlling interests	0.86	0.78	0.67	2.90
XVII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,960.61	1,960.57	1,959.76	1,960.57
XVIII	Other Equity excluding Revaluation Reserve	-	-	-	39,975.76
XIX	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinuing operations) (non-annualised) :				
	(1) Basic (in Rs.)	(4.18)	(2.54)	5.82	13.04
	(2) Diluted (in Rs.)	(4.18)	(2.54)	5.81	13.04

Notes:

- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Thursday, 27th July, 2023.
- The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to limited review by the Statutory Auditors of the Company and they have expressed an unmodified review report.
- The Group has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The figures for the Quarter ended 31st March, 2023 are the balancing figures between audited figures in respect of the full financial year 2022-23 and the published year to date figures upto the third quarter of the financial year 2022-23. Also the figures upto the end of the third quarter had only been reviewed and not subjected to audit.
- The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards employment and post-employment benefits. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Group will assess the impact and its valuation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- In April 2023, Astec LifeSciences launched a new state-of-the-art research and development (R&D) Center in Maharashtra, named the 'Adi Godrej Center for Chemical Research and Development'. R&D Center is equipped with a synthesis lab for product synthesis, a formulation lab to develop new formulations and also houses sophisticated process safety infrastructure to undertake safe and sustainable chemical reactions. The new facility will focus on new product generation, process optimization & scale-up along with product life-cycle management and help Astec in providing services to innovator companies in the contract development & manufacturing space (CDMO).

For Astec LifeSciences Limited

ANURA G ROY Digitally signed by ANURAG ROY
Date: 2023.07.27
14:25:26 +05'30'

Anurag Roy

Whole – Time Director & Chief Executive Officer

DIN : 07444595

Place : Mumbai

Date : July 27th, 2023

BURJIS TEHMURASP PARDIWALA Digitally signed by BURJIS TEHMURASP PARDIWALA
Date: 2023.07.27
14:39:12 +05'30'



Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com



Additional disclosures as per Clause 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars	STANDALONE			
		Quarter Ended			Year ended
		30-Jun-23	31-Mar-23	30-Jun-22	31-Mar-23
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Current Ratio (refer note 1)	0.81	0.95	1.08	0.95
II	Net Worth (in Rs. Lakh)	41,064.34	41,879.37	40,755.93	41,879.37
III	Outstanding redeemable preference shares (quantity and value)	-	-	-	-
IV	Net profit after tax	(820.70)	(499.53)	1,138.98	2,552.04
V	Basic Earnings per share	(4.19)	(2.55)	5.81	13.02
VI	Diluted Earnings per share	(4.19)	(2.55)	5.81	13.02
VII	Capital Redemption Reserve (in Rs. Lakh)	0.30	0.30	0.30	0.30
VIII	Debt Equity ratio (refer note 1)	1.03	0.81	0.87	0.81
IX	Debt Service Coverage Ratio (DSCR) (refer note 1)	0.49	0.97	5.78	1.25
X	Interest Service Coverage Ratio (ISCR) (refer note 1)	1.19	1.42	6.19	3.88
XI	Long term debt to working capital (refer note 1)	*	3.33	0.26	3.33
XII	Bad debts to Account receivable ratio (refer note 1)	-	-	-	-
XIII	Current liability ratio (refer note 1)	0.89	0.86	0.96	0.86
XIV	Total debts to total assets (refer note 1)	0.42	0.35	0.36	0.35
XV	Debtors turnover (refer note 1)	3.52	3.11	2.70	2.75
XVI	Inventory turnover (refer note 1)	2.08	1.82	3.86	2.61
XVII	Operating margin (%)	2.2%	4.3%	15.3%	12.1%
XVIII	Net profit margin (%)	-5.7%	-3.9%	6.2%	4.1%

* Net working capital is negative

1 Pursuant to SEBI Operational Circular for Issue and Listing of Non-Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated 10th August, 2021, the Company has listed Commercial Papers on National Stock Exchange (NSE).

The Company is rated by leading credit agency ICRA and India Ratings & Research. ICRA has assigned the rating “[ICRA] A1+” and “[ICRA] AA-” for its short term facilities (including commercial paper) and long term facilities respectively. India Ratings & Research has assigned “[IND] AA-” for its Non-Convertible Debentures (NCDs).

Formulae for computation of ratios:

Current ratio : Current assets / Current liabilities

Net Worth: As per Companies Act, 2013

Debt Equity ratio : Total Debt / Shareholder’s Equity

Debt Service Coverage Ratio : (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / (Interest & Lease Payments + Principal Repayments)

Interest service coverage ratio: (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / Interest expense

Long term debt to working capital : (Non-current borrowings+Current maturities of long term debt) / (Current Assets - (Current liabilities-Current maturities of long term debt))

Bad debts to Account receivable ratio : Bad debts including provision for doubtful debts / Average Trade receivable.

Current liability ratio : (Current liabilities-Current maturities of Long term Debt) / Total liabilities

Total debts to total assets : Total borrowings / Total assets

Debtors turnover : Net Credit Sales / Average Trade Receivable (annualised)

Inventory turnover : Net Sales/ Average Inventory (annualised).

Operating margin (%): Earnings before Interest, Tax & Depreciation & Amortisation less Other Income/Revenue from Operations

Net Profit margin(%): Profit after Tax(after exceptional items)/Revenue from Operations

**ANURAG
ROY**

Digitally signed by
ANURAG ROY
Date: 2023.07.27
14:25:40 +05'30'

**BURJIS
TEHMURASP
PARDIWALA**

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2023.07.27
14:39:32 +05'30'



Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

Additional disclosures as per Clause 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015



Sr. No	Particulars	CONSOLIDATED			
		Quarter Ended			Year ended
		30-Jun-23	31-Mar-23	30-Jun-22	31-Mar-23
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Current Ratio (refer note 1)	0.81	0.95	1.08	0.95
II	Net Worth (in Rs. Lakh)	41,122.20	41,936.32	40,808.83	41,936.32
III	Outstanding redeemable preference shares (quantity and value)	-	-	-	-
IV	Net profit after tax	(818.60)	(497.51)	1,140.66	2,559.40
V	Basic Earnings per share	(4.18)	(2.54)	5.82	13.04
VI	Diluted Earnings per share	(4.18)	(2.54)	5.81	13.04
VII	Capital Redemption Reserve (in Rs. Lakh)	0.30	0.30	0.30	0.30
VIII	Debt Equity ratio (refer note 1)	1.03	0.81	0.87	0.81
IX	Debt Service Coverage Ratio (DSCR) (refer note 1)	0.49	0.97	5.81	1.25
X	Interest Service Coverage Ratio (ISCR) (refer note 1)	1.19	1.42	6.20	3.89
XI	Long term debt to working capital (refer note 1)	*	3.16	0.25	3.16
XII	Bad debts to Account receivable ratio (refer note 1)	-	-	-	-
XIII	Current liability ratio (refer note 1)	0.89	0.86	0.96	0.86
XIV	Total debts to total assets (refer note 1)	0.42	0.35	0.36	0.35
XV	Debtors turnover (refer note 1)	3.52	3.11	2.70	2.75
XVI	Inventory turnover (refer note 1)	2.08	1.82	3.86	2.61
XVII	Operating margin (%)	2.2%	4.3%	15.3%	12.1%
XVIII	Net profit margin (%)	-5.7%	-3.9%	6.2%	4.1%

* Net working capital is negative

- 1 Pursuant to SEBI Operational Circular for Issue and Listing of Non-Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated 10th August, 2021, the Company has listed Commercial Papers on National Stock Exchange (NSE).

The Company is rated by leading credit agency ICRA and India Ratings & Research. ICRA has assigned the rating "[ICRA] A1+" and "[ICRA] AA-" for its short term facilities (including commercial paper) and long term facilities respectively. India Ratings & Research has assigned "[IND] AA-" for its Non-Convertible Debentures (NCDs).

Formulae for computation of ratios:

Current ratio : Current assets / Current liabilities

Net Worth: As per Companies Act, 2013

Debt Equity ratio : Total Debt / Shareholder's Equity

Debt Service Coverage Ratio : (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / (Interest & Lease Payments + Principal Repayments)

Interest service coverage ratio: (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / Interest expense

Long term debt to working capital : (Non-current borrowings+Current maturities of long term debt) / (Current Assets - (Current liabilities-Current maturities of long term debt))

Bad debts to Account receivable ratio : Bad debts including provision for doubtful debts / Average Trade receivable.

Current liability ratio : (Current liabilities-Current maturities of Long term Debt) / Total liabilities

Total debts to total assets : Total borrowings / Total assets

Debtors turnover : Net Credit Sales / Average Trade Receivable (annualised)

Inventory turnover : Net Sales/ Average Inventory (annualised).

Operating margin (%): Earnings before Interest, Tax & Depreciation & Amortisation less Other Income/Revenue from Operations

Net Profit margin(%): Profit after Tax(after exceptional items)/Revenue from Operations

ANURA Digitally signed
by ANURAG ROY
G ROY Date: 2023.07.27
14:25:53 +05'30'

BURJIS Digitally signed by
TEHMURASP BURJIS TEHMURASP
PARDIWALA PARDIWALA
Date: 2023.07.27
14:39:46 +05'30'

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai – 400063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited standalone financial results of Astec LifeSciences Limited for the quarter ended 30 June 2023 pursuant to Regulation 33 and Regulation 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021

To the Board of Directors of Astec LifeSciences Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Astec LifeSciences Limited (hereinafter referred to as “the Company”) for the quarter ended 30 June 2023 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2023 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021,

Registered Office:

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

B S R & Co. LLP

Limited Review Report (Continued)

Astec LifeSciences Limited

including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2023.07.27
14:40:30 +05'30'

Burjis Pardiwala

Partner

Mumbai

27 July 2023

Membership No.: 103595

UDIN:23103595BGTPFP6872

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai – 400063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited consolidated financial results of Astec LifeSciences Limited for the quarter ended 30 June 2023 pursuant to Regulation 33 and Regulation 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021

To the Board of Directors of Astec LifeSciences Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Astec LifeSciences Limited (hereinafter referred to as “the Parent”), and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended 30 June 2023 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021.
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement:
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2023 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Registered Office:

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Limited Review Report (Continued)

Astec LifeSciences Limited

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the interim financial information of One Subsidiary included in the Statement, whose interim financial information reflect total revenues (before consolidation adjustments) of Rs. 3.85 lakhs, total net profit after tax (before consolidation adjustments) of Rs. 2.50 lakhs and total comprehensive income (before consolidation adjustments) of Rs. 2.50 lakhs, for the quarter ended 30 June 2023, as considered in the Statement. These interim financial information has been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

8. The Statement includes the interim financial information of One Subsidiary which have not been reviewed, whose interim financial information reflect total revenues (before consolidation adjustments) of Rs. Nil, total net profit / (loss) after tax (before consolidation adjustments) of Rs. Nil and total comprehensive income (before consolidation adjustments) of Rs. Nil, for the quarter ended 30 June 2023, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2023.07.27
14:40:06 +05'30'

Burjis Pardiwala

Partner

Mumbai

27 July 2023

Membership No.: 103595

UDIN:23103595BGTPFQ8401

Limited Review Report (Continued)
Astec LifeSciences Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Astec LifeSciences Limited	Holding Company
2	Behram Chemicals Private Limited	Subsidiary Company
3	Comercializadora Agricola Agroastrachem Cia Ltda	Subsidiary Company